Bladder Cancer
If it’s your first time on this website, please read the disclaimer section.
Jun 01 – Jun 08, 2026
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
The phase II SURE-01 trial investigated neoadjuvant sacituzumab govitecan (SG) followed by radical cystectomy in 44 patients with muscle-invasive bladder cancer (MIBC) ineligible for or refusing standard chemotherapy. The study reported an overall ypT0N0-x rate of 29.5% (95% CI, 16.7 to 45.2), with enrichment in nonluminal subtypes (46% vs 14% in luminal), and a 24-month event-free survival rate of 71.4% (95% CI, 58 to 87.8). SG, at a reduced dose of 7.5 mg/kg, demonstrated activity and a manageable safety profile, corroborating TROP2 as a suitable target for MIBC treatment. This offers a promising neoadjuvant option for MIBC patients who cannot receive standard chemotherapy, potentially improving outcomes in a high-risk population.
10.1200/JCO-26-00142
May 25 – Jun 01, 2026
Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This single-arm phase II trial (SAKK 06/19) investigated neoadjuvant intravesical recombinant BCG (rBCG) combined with chemo-immunotherapy (atezolizumab, cisplatin/gemcitabine) in 47 patients with cT2-T4a N0-1 muscle-invasive bladder cancer (MIBC) prior to radical cystectomy. The primary endpoint, centrally reviewed pathological complete response (pCR), was 68% (27/40), with a pathological overall response (PaR) of 83% (33/40). These high response rates are clinically significant for MIBC, a cancer with substantial morbidity, suggesting a promising new neoadjuvant strategy. The findings warrant further investigation in prospective randomized trials to potentially improve outcomes for MIBC patients.
10.1200/JCO-26-00845
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase I/II NEMIO study evaluated the efficacy and safety of neoadjuvant ddMVAC combined with durvalumab ± tremelimumab in 119 patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy. Key findings showed overall Bayesian posterior mean pathologic complete response (pCR) rates of 48.70% with doublet and 46.27% with triplet therapy, with PD-L1-high tumors achieving 68.25% pCR. Grade ≥3 treatment-related adverse events occurred in 40.95% overall (30.48% doublet; 49.63% triplet), while 2-year event-free and overall survival rates were encouraging. These results suggest neoadjuvant ddMVAC plus durvalumab is a promising chemoimmunotherapy strategy for localized MIBC, warranting further comparative trials, noting that adding tremelimumab increased toxicity without improving pCR.
10.1200/JCO-25-03045
May 18 – May 25, 2026
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This multicenter, phase III randomized trial investigated adjuvant radiotherapy (RT) versus observation after radical cystectomy and chemotherapy in 153 high-risk muscle-invasive bladder cancer (MIBC) patients. After a median 47-month follow-up, adjuvant RT significantly improved 2-year locoregional recurrence-free survival (87.1% vs 76.0%, HR 0.43, p=.04). Trends for improved disease-free, bladder cancer-specific, and overall survival were also observed without additional severe toxicity. These findings suggest adjuvant pelvic IMRT can enhance locoregional control in high-risk MIBC, offering a crucial strategy to reduce recurrence in clinical practice.
10.1200/JCO-25-02093
Apr 13 – Apr 20, 2026
Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This pooled analysis of 30 prospective studies with over 2.5 million participants examined associations between body size and bladder cancer risk, finding that overweight and obesity were associated with increased risk specifically in males, with hazard ratios of 1.08 and 1.16 respectively, while no significant associations were found for females. The study employed multivariable Cox regression and random-effects meta-analysis, adjusting for smoking and other confounders, providing strong evidence for sex-specific risk patterns. For clinicians focused on cancer research, this offers important epidemiological evidence linking modifiable risk factors (body size) to a specific cancer type, with clear implications for prevention strategies. The primary implication is that public health interventions targeting overweight and obesity, alongside smoking cessation, could reduce bladder cancer incidence, particularly in male populations.
10.1200/JCO-25-02155